SCHEMBL4121225

SCHEMBL4121225

CN(NC(=O)c1cnn2c(-c3ccc(Cl)cc3)c(-c3ccccc3Cl)cnc12)c1ccccn1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 5/20 0.36
JAK1 P23458 5/20 0.36
SMN1; SMN2 Q16637 4/20 0.36
RAB9A P51151 4/20 0.36
MAPT P10636 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
IRAK4 Q9NWZ3 4/20 0.35
TYK2 P29597 4/20 0.34
NPC1 O15118 3/20 0.34
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 1/20 0.34
JAK3 P52333 3/20 0.34
LRRK2 Q5S007 1/20 0.34
EPHA2 P29317 1/20 0.33
GSK3A P49840 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
PKM P14618 1/20 0.33
HSD17B10 Q99714 1/20 0.33
LMNA P02545 1/20 0.33
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4120614 0.91 SMN1; SMN2 (0.35) JAK2JAK1SMN1; SMN2RAB9AMAPT
SCHEMBL4118722 0.91 LMNA (0.39) MAPTLMNAPOLB
SCHEMBL4108378 0.89 KDM4E (0.38) JAK2JAK1SMN1; SMN2RAB9AMAPT
SCHEMBL4108655 0.88 RAB9A (0.37) JAK2JAK1SMN1; SMN2RAB9AMAPT
SCHEMBL4108662 0.88 LMNA (0.35) SMN1; SMN2RAB9AMAPTNPC1KDM4E
SCHEMBL4118485 0.88 RAB9A (0.40) JAK2JAK1SMN1; SMN2RAB9AMAPT
SCHEMBL4126440 0.85 JAK2 (0.37) JAK2JAK1SMN1; SMN2RAB9AMAPT
SCHEMBL31061014 0.85 JAK2 (0.37) JAK2JAK1SMN1; SMN2RAB9AMAPT
SCHEMBL4118052 0.83 CNR2 (0.41) SMN1; SMN2RAB9AMAPTIRAK4NPC1
SCHEMBL2086773 0.83 F10 (0.34) SMN1; SMN2RAB9AMAPTTDP1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188097-B2 Pyrazolo[1,5-A]pyrimidine compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-05-29 US claimed
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds TANABE SEIYAKU CO., LTD. (JP) 2009-03-12 US claimed
US-8188097-B2 Pyrazolo[1,5-A]pyrimidine compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-05-29 US disclosed
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds TANABE SEIYAKU CO., LTD. (JP) 2009-03-12 US disclosed
EP-1945220-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS Mitsubishi Tanabe Pharma Corporation (JP) 2008-07-23 EP disclosed
WO-2007046548-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds RECQL, QTRT1, DPYD JAK2 59/4885JAK1 116/4885SMN1; SMN2 3307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.